224 related articles for article (PubMed ID: 17179819)
1. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.
Takeyama M; Sakurai Y; Shima M; Matsumoto T; Nogami K; Tanaka I; Takeda T; Giddings JC; Yoshioka A
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):1-7. PubMed ID: 17179819
[TBL] [Abstract][Full Text] [Related]
2. Use of rotation thromboelastometry (ROTEM) to achieve successful treatment of polytrauma with fibrinogen concentrate and prothrombin complex concentrate.
Schöchl H; Forster L; Woidke R; Solomon C; Voelckel W
Anaesthesia; 2010 Feb; 65(2):199-203. PubMed ID: 19995349
[TBL] [Abstract][Full Text] [Related]
3. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
[TBL] [Abstract][Full Text] [Related]
4. ROTEM monitoring of activated and non-activated prothrombin complex concentrate correction of dilutional coagulopathy.
Elvstam O; Berntorp E; Schött U
Scand J Clin Lab Invest; 2016; 76(3):202-7. PubMed ID: 26898225
[TBL] [Abstract][Full Text] [Related]
5. The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass.
Reinhöfer M; Brauer M; Franke U; Barz D; Marx G; Lösche W
Blood Coagul Fibrinolysis; 2008 Apr; 19(3):212-9. PubMed ID: 18388501
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of hirudin on thrombosis induced by prothrombin complex concentrates.
Klöcking HP; Schulze-Riewald H; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):106-9. PubMed ID: 2459002
[TBL] [Abstract][Full Text] [Related]
7. Prothrombin complex concentrates: a brief review.
Samama CM
Eur J Anaesthesiol; 2008 Oct; 25(10):784-9. PubMed ID: 18538049
[TBL] [Abstract][Full Text] [Related]
8. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
9. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate.
Dickneite G; Doerr B; Kaspereit F
Anesth Analg; 2008 Apr; 106(4):1070-7, table of contents. PubMed ID: 18349175
[TBL] [Abstract][Full Text] [Related]
11. Interpreting coagulation assays.
Green D
Blood Coagul Fibrinolysis; 2010 Sep; 21 Suppl 1():S3-6. PubMed ID: 20855988
[TBL] [Abstract][Full Text] [Related]
12. Heparin-induced effects of prothrombin complex concentrates in thromboelastometry.
Scharbert G; Thaler U; Weilnböck C; Wetzel L; Kozek-Langenecker S
Wien Klin Wochenschr; 2012 May; 124(9-10):320-5. PubMed ID: 22576961
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
14. Assessment of thrombogenicity of activated and non-activated prothrombin concentrates in a rat model.
Silberman S; Fareed J; Walenga J
Br J Exp Pathol; 1986 Aug; 67(4):597-604. PubMed ID: 3091059
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the sensitivity of an in vitro high frequency ultrasound device to monitor the coagulation process: study of the effects of heparin treatment in a murine model.
Callé R; Rochefort GY; Desbuards N; Plag C; Antier D; Ossant F
Ultrasound Med Biol; 2010 Feb; 36(2):295-305. PubMed ID: 20045589
[TBL] [Abstract][Full Text] [Related]
16. The endothelial cell and the factor VIII bypassing activity of prothrombin complex concentrate.
Teitel JM; Ni HY; Freedman JJ; Garvey MB
Thromb Haemost; 1988 Oct; 60(2):226-9. PubMed ID: 3146140
[TBL] [Abstract][Full Text] [Related]
17. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography.
Sørensen B; Ingerslev J
Haemophilia; 2005 Nov; 11 Suppl 1():1-6. PubMed ID: 16219042
[TBL] [Abstract][Full Text] [Related]
18. Different Heparin Contents in Prothrombin Complex Concentrates May Impair Blood Clotting in Outpatients With Ventricular Assist Devices Receiving Phenprocoumon.
Felli A; Zeidler P; Jilma B; Opfermann P; Holaubek C; Zimpfer D; Wadowski PP; Steinlechner B
J Cardiothorac Vasc Anesth; 2016 Jan; 30(1):96-101. PubMed ID: 26613641
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
Levi M; Toh CH; Thachil J; Watson HG
Br J Haematol; 2009 Apr; 145(1):24-33. PubMed ID: 19222477
[TBL] [Abstract][Full Text] [Related]
20. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
Prowse CV; Boffa MC; Guthrie C; Pepper DS
Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
